Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemfibrozil in CAPD patients.

A De Vecchi1, A Scalamogna, C Pini

  • 1Divisione di Nefrologia IRCCS Ospedale Maggiore, Italy.

Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial.

AIDS and behavior·2022
Same author

Magnetic monopole density and antiferromagnetic domain control in spin-ice iridates.

Nature communications·2022
Same author

Head down tilt 15° in experimental intracerebral hemorrhage: a randomized noninferiority safety trial.

European journal of neurology·2020
Same author

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Factor X deficiency and pregnancy: case report and counselling.

Haemophilia : the official journal of the World Federation of Hemophilia·2020
Same author

Individual Patient-specific Planning of Minimally Invasive Transcatheter Intervention for Heart Valve Disease.

EClinicalMedicine·2019
Same journal

Treatment of a Dialysate Leak by Simultaneous Catheter Removal and Replacement in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

A Rare Complication During Percutaneous Peritoneal Dialysis Catheter Insertion: Intravesical Placement.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Is It Safe to Initiate Peritoneal Dialysis Treatment Immediately After Percutaneous Catheter Placement?

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Better Healing of the Exit Site with Negative-Pressure Wound Therapy.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

When Love Hurts, It Leaves No Options! An Unusual Case of Pasteurella Peritoneal Dialysis Peritonitis Causing Severe Intra-abdominal Adhesions Preventing a Future Peritoneal Dialysis Option.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Neisseria mucosa Peritonitis in the Setting of a Migrated Intrauterine Device.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
See all related articles

Gemfibrozil effectively lowered triglyceride levels in CAPD patients. Despite some dropouts due to compliance, the drug demonstrated significant improvements in lipid profiles with no observed side effects.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) often experience dyslipidemia, particularly elevated triglyceride levels.
  • Hypertriglyceridemia is a significant risk factor for cardiovascular disease in this patient population.

Purpose of the Study:

  • To evaluate the efficacy and safety of gemfibrozil in managing hypertriglyceridemia in CAPD patients.
  • To assess the impact of gemfibrozil on various lipid parameters, including triglycerides, VLDL, LDL, HDL, Apo A1, and Apo B.

Main Methods:

  • A daily oral dose of 600 mg gemfibrozil was administered to 28 CAPD patients with baseline triglyceride levels > 200 mg/dl.
  • Patients initially underwent a 2-month low-fat, low-calorie diet before gemfibrozil treatment.

Related Experiment Videos

  • Lipid profiles were monitored throughout the study period.

    • Main Results:

    • Gemfibrozil significantly reduced serum total triglycerides (p=0.003), VLDL triglycerides (p<0.005), and LDL triglycerides (p=0.004).
    • A significant increase in serum HDL cholesterol (p<0.001) and apolipoprotein A1 (p<0.001) was observed.
    • Serum VLDL cholesterol decreased (p=0.003) and apolipoprotein B decreased (p<0.001).
    • No clinical or laboratory side effects were reported in patients who completed the study.

    Conclusions:

    • Gemfibrozil is an effective treatment for hypertriglyceridemia in CAPD patients, leading to significant improvements in lipid profiles.
    • Observed dropouts were primarily attributed to poor patient compliance rather than drug-related side effects.
    • Gemfibrozil represents a safe and beneficial therapeutic option for managing dyslipidemia in CAPD patients.